B-Type natriuretic peptide (BNP) has established itself as an important cardiovascular and cardio renal biomarker. Stroke is an emergency having high mortality, morbidity, social and economic implications. Acute ischemic stroke (AIS) accounts for approximately 70% of all strokes and is caused by embolic or atherosclerotic occlusion in the cerebral vessels. Identification of a biomarker for risk, severity and prognosis of stroke would be of great benefit. The mechanism by which the plasma levels of BNP are increased in patients with AIS independently of heart diseases is not clearly defined but the levels of BNP has shown a strong correlation with cardio-embolic stroke and has established its role as a surrogate marker for the same. Biomarkers like BNP should be used to supplement clinically guided therapy and not to substitute it. Proper interpretation of BNP would surely make the diagnosis, management and risk stratification better for stroke subjects.